Intuitive Surgical (NASDAQ:ISRG) Receives “Overweight” Rating from Piper Sandler

Intuitive Surgical (NASDAQ:ISRG)‘s stock had its “overweight” rating reissued by Piper Sandler in a report issued on Friday, Benzinga reports. They presently have a $538.00 target price on the medical equipment provider’s stock, up from their previous target price of $495.00. Piper Sandler’s price objective would indicate a potential upside of 3.23% from the company’s previous close.

A number of other equities analysts also recently issued reports on the company. Morgan Stanley increased their target price on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Mizuho raised their price objective on Intuitive Surgical from $440.00 to $500.00 in a research note on Thursday. Stifel Nicolaus raised their price objective on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research note on Friday, July 19th. Citigroup raised their price objective on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Finally, Leerink Partners raised their price objective on Intuitive Surgical from $489.00 to $502.00 in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $513.74.

Intuitive Surgical Stock Up 10.0 %

Shares of NASDAQ ISRG opened at $521.15 on Friday. The stock has a market cap of $184.85 billion, a PE ratio of 94.07, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. Intuitive Surgical has a 52-week low of $254.85 and a 52-week high of $523.34. The business has a 50-day moving average price of $483.85 and a 200 day moving average price of $438.17.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same period last year, the firm earned $1.18 EPS. The firm’s revenue for the quarter was up 14.5% on a year-over-year basis. Sell-side analysts anticipate that Intuitive Surgical will post 5.22 earnings per share for the current year.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Robert Desantis sold 376 shares of the company’s stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $446.60, for a total value of $167,921.60. Following the completion of the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at $2,458,979.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Amy L. Ladd sold 450 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the transaction, the director now directly owns 821 shares of the company’s stock, valued at approximately $402,519.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Robert Desantis sold 376 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $446.60, for a total value of $167,921.60. Following the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,458,979.60. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 53,120 shares of company stock valued at $25,528,753. Company insiders own 0.90% of the company’s stock.

Hedge Funds Weigh In On Intuitive Surgical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ISRG. Ridgewood Investments LLC bought a new position in Intuitive Surgical during the 2nd quarter valued at $26,000. Godsey & Gibb Inc. lifted its position in shares of Intuitive Surgical by 140.0% during the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 35 shares during the last quarter. Creekmur Asset Management LLC lifted its position in shares of Intuitive Surgical by 200.0% during the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 42 shares during the last quarter. LGT Financial Advisors LLC lifted its position in shares of Intuitive Surgical by 415.4% during the 2nd quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 54 shares during the last quarter. Finally, Delos Wealth Advisors LLC lifted its position in shares of Intuitive Surgical by 380.0% during the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares during the last quarter. 83.64% of the stock is owned by institutional investors.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.